Company / R&D per Share
Haemonetics R&D per Share History
FY2017-FY2026 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.13
FY2026
5-year range
$0.97 / $1.24
FY2022-FY2026
Trend
-
vs FY2025
Sector context
#67 of 108
Health Care
What the data says
At $1.13, Haemonetics's r&d per share ranks #67 of 108 in the Health Care sector. Improved from $1.06 to $1.13 over the past 3 years.
Based on SEC 10-K filings.
1.13 in FY2026 with a 5-year CAGR of +4.4%.
Improved from $1.06 to $1.13 over the past 3 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +2.2%
- 5-Year CAGR
- +4.4%
- 10-Year CAGR
- -
Sector benchmark
#67 of 108 in Health CareTop 62% of 108This company $1.13 Sector average $2.07
▼
-45.6% below sector average
Key checks
Key Insights
- Ranks #67 out of 108 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2024.
- Lowest r&d per share in the period was in FY2019.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2026 | $1.13 | - |
| FY2025 | - | - |
| FY2024 | $1.24 | +17.4% |
| FY2023 | $1.06 | +8.6% |
| FY2022 | $0.97 | +7.0% |
| FY2021 | $0.91 | +42.3% |
| FY2020 | $0.64 | +7.5% |
| FY2019 | $0.60 | -12.8% |
| FY2018 | $0.68 | -11.3% |
| FY2017 | $0.77 | +6.0% |
As of FY2026 · SEC 10-K · Updated Jun 30, 2026